This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Zenas BioPharma is beefing up its pipeline with three experimental autoimmune medicines from China’s InnoCare Pharma, including a treatment for multiple sclerosis that has already begun Phase 3 testing. InnoCare will receive as much as $100 million in upfront and near-term cash payments, including for goals expected to be achieved in 2026, Zenas s ...